Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronie's Disease
Date:10/11/2010

ients.  XIAFLEX will be administered two times a week every six weeks for up to four treatment cycles (2 x 4).  Each treatment cycle will be followed by a penile modeling procedure.  Patients will be followed for 52 weeks post-first injection in the double-blind studies and for 36 weeks in the open label trial.  

The trials' co-primary endpoints are the change from baseline in the Peyronie's disease bother domain of the Peyronie's Disease Questionnaire (PDQ) compared to placebo and percent improvement from baseline in penile curvature compared to placebo.  The PDQ will have at least three domains, which will include Peyronie's disease bother, severity of psychological and physical symptoms of Peyronie's disease, and penile pain.  Safety measurements will include adverse event monitoring, immunogenicity testing and clinical labs.

"We are encouraged by the clinical profile of XIAFLEX, which emerged from our earlier phase IIb clinical trial in Peyronie's disease.  XIAFLEX was well-tolerated and produced clinically significant reductions in both penile curvature and disease bother," said Dr. Jim Tursi, Auxilium's Vice President of Clinical Research & Development.  "Over the last six months, our team, in conjunction with the U.S. Food and Drug Administration (FDA), outside experts and men with Peyronie's disease, has spent a considerable amount of time and effort to refine the PDQ, which has now been accepted for use in the phase III clinical trials by the FDA's Study Endpoint and Label Development (SEALD) Division."

Conference Call and WebcastAuxilium will hold a webcast and conference call today, October 11, 2010 at 8:30 a.m. ET, to:

  • discuss the initiation of the global phase III program of XIAFLEX for the treatment of Peyronie's disease; and
  • update the leading indicators for the launch of XIAFLEX in Dupuytren's contracture.

  • The presentation slides to be used during the cal
    '/>"/>

    SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
    3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
    4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
    8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
    9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
    10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... NEW YORK , Aug. 28, ... a new market research report is ... Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets ... Target High Unmet Need in Newly ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
    (Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
    (Date:8/28/2014)... Calif. , Aug. 28, 2014 Amgen ... of a Biologics License Application (BLA) to the U.S. ... for the treatment of high cholesterol. Evolocumab is an ... subtilisin/kexin type 9 (PCSK9), a protein that reduces the ... "bad" cholesterol, from the blood. 1 ­ ...
    Breaking Medicine Technology:Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
    (Date:8/29/2014)... Astoria, New York, (PRWEB) August 29, 2014 ... a degenerative condition that damages the motor neurons in the ... and more of the nerve cells controlling movement are harmed, ... functions. Eventually this leads to death. , ALS is ... and 70, and as many as 30,000 Americans have the ...
    (Date:8/29/2014)... Top10BestSEOHosting.com today compares many professional ... announces that Bluehost ( http://www.bluehost.com/track/seohosts ), Arvixe, and ... for webmasters who want to buy high quality ... at affordable rates. , Bluehost is also a ... its features is that Bluehost provides quality hosting ...
    (Date:8/29/2014)... CA (PRWEB) August 29, 2014 According ... a lawsuit against Pfizer Inc., Greenstone LLC and Pfizer ... with congenital birth defects as a result of ... defect lawsuit was filed in St. Clair County Circuit ... to the lawsuit, the defendant companies allegedly concealed the ...
    (Date:8/29/2014)... Visiting Nurse Association of Northern New ... delivering comfort and companionship to terminally-ill patients and their ... continues to grow and their needs expand, the VNA ... The next Hospice Training Program will be offered on ... P.M. at VNA’s headquarters, 175 South Street in Morristown. ...
    (Date:8/29/2014)... The Winscribe Board of Directors today announced the ... from 1st September 2014. Allen previously held the position ... time of growth, there is no better person to ... Founder and Chairman of the Board. “Allen is a ... management experience gained in New Zealand, Europe and the ...
    Breaking Medicine News(10 mins):Health News:Charity Event to Raise Awareness and Donations for the ALS Foundation 2Health News:Top10BestSEOHosting.com: Bluehost, Arvixe, and Hostgator Are the Best Windows Web Hosting from the USA in 2014 2Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Zoloft Birth Defect Lawsuit 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 2Health News:VNA Offers Rewarding Hospice Volunteer Opportunity 3Health News:Winscribe Names Greg Allen as CEO 2
    ... Blue Cross and Blue Shield of Georgia (BCBSGA) ... reached agreement on a three-year contract, effective August ... members can continue to access Piedmont Healthcare as ... physicians, Piedmont Hospital in Atlanta, Piedmont Fayette Hospital ...
    ... North America,s largest annual interdisciplinary academic conference kicks off in ... Carleton University to present and debate research from across the ... will be held this Friday at 10:30 a.m. in the ... of what to expect. , Nathalie Des Rosiers, president of ...
    ... By combining the expertise of its ... (BEZ.L) has developed enhanced management liability coverage ... of healthcare organizations, including hospitals, long term ... is an adaptation of Beazley,s successful BeazleyOne ...
    ... calls to consider reducing the legal drinking age, a new University of ... births among young people. , ... Athens, Ga. (Vocus) May 21, 2009 ... new University of Georgia study finds that lower drinking ages ...
    ... May 21 For the second year in a ... to donate blood through the Red Cross by joining ... Red Cross Racing is a program designed to increase ... they donate. Participants of this program can get points for ...
    ... shows droplets rubbed into skin prevented infections , , THURSDAY, ... rubbed into the skin appear to protect against ear ... , If this approach proves effective in humans, it ... infections, the researchers noted. , Three groups of chinchillas ...
    Cached Medicine News:Health News:Blue Cross and Blue Shield of Georgia and Piedmont Healthcare Announce Contract Renewal 2Health News:Thousands of Canada's best minds converge at Congress 2009 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 2Health News:Beazley's New Management Liability Coverage is Tailored to Unique Needs of Healthcare Organizations 3Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 2Health News:Study: Lower Legal Drinking Age Increases Poor Birth Outcomes 3Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 2Health News:NASCAR Fans Boost Blood Donations; The American Red Cross Joins 3M and Greg Biffle to Kick off Season Two 3Health News:Pediatric Ear Infection Vaccine Shows Promise 2
    The Medtronic CardioRhythm Marinr Catheter is intended for use in diagnostic electrophysiologic procedures. These catheters are designed for recording intracardiac electrograms and temporary pacing a...
    ... designed for use with our CARTO EP ... catheter houses a Biosense Webster sensor at ... time, exact location points from within the ... The NAVI-STAR electro-anatomical navigation catheter is used ...
    ... Tricuspid Mapping. Biosense Webster offers a complete ... in the atrium. The HALO XP 20-pole ... and mapping around the tricuspid annulus. The ... distal tip (on P15-FS/0 permit pacing in ...
    ... Webster is the source for a complete ... left-sided mapping - all with the quality, ... expect from the leader in catheter technology. ... specifically designed and constructed to help minimize ...
    Medicine Products: